RecallRadar

FDA Drug recall D-0021-2023

Quinapril and Hydrochlorothiazide Tablets, USP 20mg/12.5mg, 90 Tablets bottles Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hig…

On 2022-11-02 the FDA classified a Class II recall of Quinapril and Hydrochlorothiazide Tablets, USP 20mg/12.5mg, 90 Tablets bottles Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hig… by Aurobindo Pharma Usa, citing CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.

Read the official FDA Drug notice

AgencyFDA Drug
Recall numberD-0021-2023
ClassificationClass II
Statuscompleted
Initiated2022-10-05
Published2022-11-02
Last updated2026-09-13 11:52 UTC
CompanyAurobindo Pharma Usa
DistributionUS

Product

Quinapril and Hydrochlorothiazide Tablets, USP 20mg/12.5mg, 90 Tablets bottles Distributed by: Aurobindo Pharma USA, Inc. 279 Princeton-Hightstown Road East Windsor, NJ 08520, Made in India, NDC 65862-162-90

Reason

CGMP Deviations: Detection of N-Nitroso-quinapril impurity above the acceptable daily intake limit.

Identifiers

ndc65862-161-90
ndc65862-162-30
ndc65862-162-90
ndc65862-163-90
code_infoLots QE2021005-A and QE2021010-A, exp 01/2023

Status history

No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: completed.

Source

Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-0021-2023%22

RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.